Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU and Brazilian cardiology communities join forces to tackle high CVD incidence

This article was originally published in Clinica

Executive Summary

Fears that Brazil’s cardiovascular disease (CVD) profile may be following that of Europe have led the country’s cardiology society (SBC) to foster closer collaboration with the European Society of Cardiology (ESC). Brazil’s CVD mortality rates are the highest in Latin America, and around double the European average. More than a half of all Brazilians aged over 50 have hypertension, and 25% of hospitalisations in this age group are CVD-related. In a bid to help address the country’s CVD situation and the healthcare needs it generates, the ESC is to deliver an educational programme at the SBC’s annual congress, which takes place in Porto Alegre during 16-19 September 2011. For further details of these activities, see: www.escardio.org

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel